ProCE Banner Activity

CheckMate 649: Updated Results From Phase III Trial of First-line Nivolumab + CT or Ipilimumab vs CT in Advanced Gastroesophageal Cancers

Slideset Download
Conference Coverage
With additional follow-up, nivolumab + CT continued to show an OS benefit over CT alone in previously untreated patients with advanced gastroesophageal cancers.

Released: September 28, 2021

Expiration: September 27, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc